K. M. Tveit, T. Guren, B. Glimelius, P. Pfeiffer, H. Sorbye, S. Pyrhonen, et al., “Phase III Trial of Cetuximab with Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: the NORDIC-VII Study,” Journal of Clinical Oncology, Vol. 30, No. 15, 2012, pp. 1755-1762. doi:10.1200/JCO.2011.38.0915

has been cited by the following article:

• TITLE: Metastatic Colorectal Cancer: Optimizing Treatment with Anti-EGFR Monoclonal Antibody

  AUTHORS: Ka-On Lam, Victor Ho-Fun Lee

  KEYWORDS: Colorectal Cancer; Epidermal Growth Factor Receptor; Cetuximab; Panitumumab; Strategy

  JOURNAL NAME: Journal of Cancer Therapy, Vol.3 No.6A, November 30, 2012

  ABSTRACT: Colorectal cancer remains a major cause of morbidity and mortality worldwide despite substantial improvement in the standard of care. Although surgical resection in selected patients may potentially be curative, systemic therapy is the only choice of treatment for most patients with metastatic colorectal cancer. Anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody has established its role in the systemic therapy of metastatic colorectal cancer through multiple well-designed clinical trials and yet, the optimal use of anti-EGFR monoclonal antibody is undefined. This article serves to review the available evidence for anti-EGFR monoclonal antibodies and to speculate optimal strategy for their uses.